Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Deferasirox Formulations in Iron Overload

June 28th 2016

MDS: Iron Chelating Options

June 28th 2016

Deciding When to Treat Excess Iron

June 28th 2016

Improving Quality of Life and Survival in Patients with MDS

June 28th 2016

Monitoring Patients with Iron Overload

June 28th 2016

Excess Iron in MDS

June 28th 2016

Stem Cell Transplantation in Patients with MDS

June 28th 2016

The Effects of Blood Transfusions on Iron Accumulation

June 28th 2016

Classification and Characteristics of MDS

June 28th 2016

Disease Characteristics in MDS

June 28th 2016

Overview and Historical Perspective of MDS

June 28th 2016

Dr. Jorge Sierra on Risk Adapted Therapy in AML

June 23rd 2016

New Criteria and Novel Agents May Help Spur MDS Advances

June 18th 2016

Although knowledge about the underlying biology of myelodysplastic syndromes has expanded rapidly in recent years, translating those findings into advances in the diagnosis and management of patients remains a significant challenge.

Novel T-Cell Engineering Strategy Aims to Reduce GVHD in Lymphoma Transplantations

June 14th 2016

This pilot trial is the first of its type to investigate T cell receptor alpha/beta-depleted and CD19-depleted haploidentical stem cell grafts in relapsed/refractory lymphoma patients.

Inotuzumab Ozogamicin Improves Outcomes in Relapsed/Refractory ALL

June 13th 2016

Inotuzumab ozogamicin demonstrated significantly improved progression-free survival and complete remission rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia.

Antibodies From Cured AML Patients Kill Leukemia Cells

June 12th 2016

Patients with acute myeloid leukemia who are cured after allogeneic hematopoietic stem cell transplantation produce antibodies that destroy leukemia cells.

Targeted Therapies Could Revolutionize AML Treatment

June 12th 2016

A host of novel agents that target distinct molecular targets are pushing complete remission rates beyond historical boundaries for patients with acute myeloid leukemia.

Vadastuximab Talirine, HMA Combo Induces Impressive Remissions in AML

June 12th 2016

Frontline treatment with the CD33-directed antibody-drug conjugate vadastuximab talirine plus a hypomethylating agent induced deep and durable remissions for older patients with acute myeloid leukemia.

Stopping TKIs Proven Safe in Chronic Phase CML

June 11th 2016

Tyrosine kinase inhibitors can safely be halted in select patients with chronic phase chronic myeloid leukemia followed a maintained deep molecular remission.

Blinatumomab Nearly Doubles Survival in Acute Lymphoblastic Leukemia

June 11th 2016

The median overall survival with the anti-CD19 immunotherapy blinatumomab was 7.7 months versus 4 months with standard chemotherapy in patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to results from the phase III TOWER study.